Part D premiums set to decline for 3rd straight year, CMS says

A document that reads 'Medicare Part D'
The Centers for Medicare & Medicaid Services is projecting lower Part D premiums for the third straight year. (Getty/designer491)

Average Medicare Part D premiums are set to decrease for the third year in a row, the Trump administration announced Tuesday. 

The Centers for Medicare & Medicaid Services (CMS) projected premiums for 2020 to be an average of $30, a decline of 13% from $34.70 in 2017. That decrease saves beneficiaries $1.9 billion in premium costs, the agency said. 

Part D enrollment has increased in tandem, according to CMS, and is up 12.2% since 2017. Trump administration officials touted steps taken under President Donald Trump to reduce costs as key to these figures. 

Case Study

Across-the-Board Impact of an OB-GYN Hospitalist Program

A Denver facility saw across-the-board improvements in patient satisfaction, maternal quality metrics, decreased subsidy and increased service volume, thanks to the rollout of the first OB-GYN hospitalist program in the state.

“Medicare Part D plans continue to be extremely popular, and the president is delivering improvements to Part D, offering plans more ways to provide low-cost options and delivering patients more transparency on drug prices,” Department of Health and Human Services (HHS) Secretary Alex Azar said in a statement. 

RELATED: Generics more expensive than branded drugs on Part D, study says 

CMS noted several steps it has taken with the goal of driving down Part D costs, including:  

  • Eliminating the so-called pharmacy “gag clause,” which prohibited pharmacists from providing information about lower-cost alternatives outside their insurance coverage

  • Cutting down the maximum amount that Part D beneficiaries pay for biosimilar products

  • Removing requirements that Part D plans must be “meaningfully” different from one another, allowing more plans to come to market

  • Mandating that beneficiaries’ explanation of benefits documents include price increases and offer lower-cost therapeutic alternatives

Drug price reform has been a cornerstone of the Trump White House’s healthcare agenda, though HHS has run into trouble with some of its most headline-grabbing changes: namely, forcing drug companies to include list prices in advertisements and eliminating legal protections for drug rebates negotiated by pharmacy benefit managers. 

RELATED: White House mulling order that would slash Medicare drug prices—report  

The rule on TV advertisements was spiked by a federal judge, and HHS pulled the rebate rule amid trepidation from the president that it could lead to premium hikes in Part D. 

CMS Administrator Seema Verma said in a statement that seeing several years of premium declines is the fruit of this labor. 

“Part D plans are having to prove their value to beneficiaries—the actions that CMS has taken to strengthen the Medicare prescription drug program are working to drive down costs for seniors,” Verma said. 

Suggested Articles

Bernie Sanders' crushing win in Nevada led to stocks for payers and providers taking a tumble on Wall Street.

Emory Healthcare in Atlanta is bringing the first 5G-enabled healthcare lab up online this week.

The Trump administration’s top Medicaid official has been increasingly critical of the entitlement program she has overseen for three years.